Company Overview of Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of antibacterial drugs. The company offers Minocin IV, a Minocycline for injection to wholesale pharmaceutical distributors in the United States. It is also developing RPX-602, a reformulation of Minocin IV; and Carbavance, an investigational agent that is a combination of a beta-lactamase inhibitor with a carbapenem. The company was founded in 2011 and is based in San Diego, California. As of December 3, 2013, Rempex Pharmaceuticals, Inc. operates as a subsidiary of The Medicines Company.
11535 Sorrento Valley Road
San Diego, CA 92121
Founded in 2011
Key Executives for Rempex Pharmaceuticals, Inc.
Chief Financial Officer and Vice President
Chief Scientific Officer and Senior Vice President of Research & Development
Vice President of Clinical Operations
Compensation as of Fiscal Year 2014.
Rempex Pharmaceuticals, Inc. Key Developments
Rempex Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-26-2015 02:30 PM
Jan 28 15
Rempex Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-26-2015 02:30 PM. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Daniel D. Burgess, Chief Executive Officer, President and Director.
Rempex Pharmaceuticals, Inc. Enters into an Agreement with the Biomedical
Feb 5 14
Rempex Pharmaceuticals, Inc. entered into an agreement with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, which provides up to $89.8 million in funding to support the development of Carbavance. Carbavance is a combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor for treatment of multi-drug resistant (MDR) gram-negative infections. The BARDA Agreement is a cost-sharing arrangement that consists of an initial base period and seven option periods that BARDA may exercise in its sole discretion pursuant to the BARDA Agreement. The BARDA Agreement provides for initial commitment by BARDA of an aggregate of $19.8 million for the initial base period and the first option period, and up to an additional $70.0 million if the remaining six option periods are exercised by BARDA. Under the cost-sharing arrangement, Rempex will be responsible for a designated portion of the costs associated with each period of work. If all option periods are exercised by BARDA, the estimated period of performance would be extended until approximately July 31, 2019. BARDA is entitled to terminate the projects under the BARDA Agreement for convenience at any time and is not obligated to provide continued funding beyond current year amounts from Congressionally approved annual appropriations. The total award under the BARDA Agreement will support non-clinical development activities, clinical studies, manufacturing and associated regulatory activities designed to obtain marketing approval of Carbavance in the U.S. for treatment of serious gram-negative infections. The BARDA Agreement also covers studies to assess the potential usefulness of Carbavance for treatment of certain gram-negative bioterrorism agents.
Rempex Pharmaceuticals, Inc. Wins $89.78 Million Federal Contract
Feb 5 14
Rempex Pharmaceuticals Inc. has won a federal contract valued at up to $89,779,821 from the U.S. Department of Health and Human Services' Office of the Secretary for research and development services on CarbavanceTM.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|